BIOTON (WSE:BIO) - Share price, News & Analysis

BIO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

BIO Stock Overview

Rewards

PE ratio (15.7x) is below the Biotechs industry average (40.2x)

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months

Latest financial reports are more than 6 months old

Does not have a meaningful market cap (PLN345M)

BIOTON Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BIOTON
Historical stock prices
Current Share Price	zł4.02
52 Week High	zł5.67
52 Week Low	zł3.29
Beta	0.27
1 Month Change	-2.55%
3 Month Change	2.69%
1 Year Change	-21.58%
3 Year Change	-6.63%
5 Year Change	-36.77%
Change since IPO	-96.74%

Recent News & Updates

Mar 21

We Think BIOTON (WSE:BIO) Is Taking Some Risk With Its Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Sep 08

The Strong Earnings Posted By BIOTON (WSE:BIO) Are A Good Indication Of The Strength Of The Business

Even though BIOTON S.A.'s ( WSE:BIO ) recent earnings release was robust, the market didn't seem to notice. We think...

Shareholder Returns

	BIO	PL Biotechs	PL Market
7D	0.9%	-0.1%	0.9%
1Y	-21.6%	-37.4%	-23.7%

Return vs Industry: BIO exceeded the Polish Biotechs industry which returned -38.9% over the past year.

Return vs Market: BIO underperformed the Polish Market which returned -14.5% over the past year.

Price Volatility

Is BIO's price volatile compared to industry and market?
BIO volatility
BIO Average Weekly Movement	13.6%
Biotechs Industry Average Movement	8.7%
Market Average Movement	7.8%
10% most volatile stocks in PL Market	15.0%
10% least volatile stocks in PL Market	5.1%

Stable Share Price: BIO is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: BIO's weekly volatility has increased from 7% to 14% over the past year.

About the Company

Founded	Employees	CEO	Website
1989	392	Jeremy Launders	https://www.bioton.pl

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities.

BIOTON Fundamentals Summary

How do BIOTON's earnings and revenue compare to its market cap?
BIO fundamental statistics
Market Cap	zł344.74m
Earnings (TTM)	zł21.93m
Revenue (TTM)	zł212.23m

15.7x

P/E Ratio

1.6x

P/S Ratio

Is BIO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIO income statement (TTM)
Revenue	zł212.23m
Cost of Revenue	zł120.38m
Gross Profit	zł91.86m
Other Expenses	zł69.93m
Earnings	zł21.93m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Aug 31, 2022

Earnings per share (EPS)	0.26
Gross Margin	43.28%
Net Profit Margin	10.33%
Debt/Equity Ratio	16.6%

How did BIO perform over the long term?

See historical performance and comparison

Valuation

Is BIOTON undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

15.72x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIO's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: BIO is good value based on its PE Ratio (15.7x) compared to the Polish Biotechs industry average (40.2x).

PE vs Market: BIO is poor value based on its PE Ratio (15.7x) compared to the Polish market (10.4x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BIO is good value based on its PB Ratio (0.6x) compared to the PL Biotechs industry average (4.6x).

Future Growth

How is BIOTON forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

42.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BIOTON has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has BIOTON performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

38.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BIO has high quality earnings.

Growing Profit Margin: BIO became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: BIO has become profitable over the past 5 years, growing earnings by 38.9% per year.

Accelerating Growth: BIO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BIO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: BIO's Return on Equity (3.5%) is considered low.

Financial Health

How is BIOTON's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: BIO's short term assets (PLN167.8M) exceed its short term liabilities (PLN147.8M).

Long Term Liabilities: BIO's short term assets (PLN167.8M) exceed its long term liabilities (PLN95.5M).

Debt to Equity History and Analysis

Debt Level: BIO's net debt to equity ratio (14.8%) is considered satisfactory.

Reducing Debt: BIO's debt to equity ratio has reduced from 24.5% to 16.6% over the past 5 years.

Debt Coverage: BIO's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: BIO's interest payments on its debt are well covered by EBIT (19.6x coverage).

Balance Sheet

Dividend

What is BIOTON current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BIO has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average board tenure

CEO

Jeremy Launders

1.58yrs

Tenure

zł488,000

Compensation

Mr. Jeremy Launders has been President of the Management Board at BIOTON S.A. since October 30, 2020.

Board Members

Experienced Board: BIO's board of directors are considered experienced (5.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/18 00:00
End of Day Share Price	2022/05/18 00:00
Earnings	2021/09/30
Annual Earnings	2020/12/31